Tivozanib is a member of the class of quinolines that is 6,7-dimethoxyquinoline substituted by a 3-chloro-4-{[(5-methyl-1,2-oxazol-3-yl)carbamoyl]amino}phenoxy group at position 4. It is a potent and selective inhibitor of VEGF receptor tyrosine kinases and was previously in clinical development for the treatment of metastatic renal cell carcinoma. It has a role as an antineoplastic agent, a vascular endothelial growth factor receptor antagonist and an apoptosis inducer. It is a member of phenylureas, a member of quinolines, an aromatic ether, a member of isoxazoles and a member of monochlorobenzenes.
